Research Explorer

Your browser does not support JavaScript or JavaScript is not enabled. Without JavaScript some functions of this webapplication may be disabled or cause error messages. To enable JavaScript, please consult the manual of your browser or contact your system administrator.

Researcher

Aster Vandierendonck

Awards & Distinctions

11 Results

2021

NOX1 inhibition attenuates the development of a pro‐tumorigenic environment in experimental hepatocellular carcinoma

Aster VandierendonckHelena DegrooteBart VanderborghtXavier VerhelstAnja GeertsLindsey DevisscherHans Van Vlierberghe

A1 Journal Article in JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

2020

Myeloid-specific IRE1alpha deletion reduces tumour development in a diabetic, non-alcoholic steatohepatitis-induced hepatocellular carcinoma mouse model

Sanne Van CampenhoutLaurentijn TillemanSander LefereAster VandierendonckSarah RaevensXavier VerhelstAnja GeertsFilip Van NieuwerburghHans Van VlierbergheLindsey Devisscher

A1 Journal Article in METABOLISM-CLINICAL AND EXPERIMENTAL

2019

Angiopoietin-2 promotes pathological angiogenesis and is a therapeutic target in murine nonalcoholic fatty liver disease

Sander LefereFrederique Van de VeldeAnne HoorensSarah RaevensSanne Van CampenhoutAster VandierendonckSara NeytBert VandeghinsteChristian VanhoveCharlotte Debbaut et al.

A1 Journal Article in HEPATOLOGY

Myeloid-specific IRE1 alpha deletion reduces tumour development in a non-alcoholic steatohepatitis-induced hepatocellular carcinoma mouse model

Sanne Van CampenhoutSander LefereAster VandierendonckXavier VerhelstAnja GeertsHans Van VlierbergheLindsey Devisscher

2018

Angiopoietin-2 as therapeutic target for pathological angiogenesis and inflammation in non-alcoholic steatohepatitis

Sander LefereF Van de VeldeSarah RaevensSanne Van CampenhoutAster VandierendonckSara NeytChristian VanhoveAnne HoorensCHRISTINE CASTELEYNXavier Verhelst et al.

Angiopoietin-2 as therapeutic target for pathological angiogenesis and inflammation in non-alcoholic steatohepatitis

Sander LefereFrederique Van de VeldeSarah RaevensSanne Van CampenhoutAster VandierendonckS NeytChristian VanhoveAnne HoorensChristophe CasteleynXavier Verhelst et al.

Angiopoietin-2 promotes pathological angiogenesis and is a novel therapeutic target in non-alcoholic fatty liver disease

Sander LefereFrederique Van de VeldeAnne HoorensSarah RaevensSanne Van CampenhoutAster VandierendonckSara NeytBert VandeghinsteChristian VanhoveCharlotte Debbaut et al.

The epigenetically regulated miR-494 associates with stem-cell phenotype and induces sorafenib resistance in hepatocellular carcinoma

Daniela PollutriClarissa PatriziSara MarinelliCatia GiovanniniElena TrombettaFerdinando A GiannoneMaurizio BaldassarreSantina QuartaYves-Paul VandewynckelAster Vandierendonck et al.

A1 Journal Article in CELL DEATH & DISEASE

2016

Next-generation proteasome inhibitor oprozomib synergizes with modulators of the unfolded protein response to suppress hepatocellular carcinoma

Yves-Paul VandewynckelCéline CouckeDebby LaukensLindsey DevisscherAnnelies ParidaensEliene BogaertsAster VandierendonckSarah RaevensXavier VerhelstChristophe Van Steenkiste et al.

A1 Journal Article in ONCOTARGET

Next-generation proteasome inhibitor oprozomib synergizes with modulators of the unfolded protein response to suppress hepatocellular carcinoma

Yves-Paul VandewynckelCéline CouckeDebby LaukensLindsey DevisscherAnnelies ParidaensEliene BogaertsAster VandierendonckSarah RaevensXavier VerhelstChristophe Van Steenkiste et al.

The unfolded protein response underlies microenvironmental stress-induced phenotype switching leading to stemness and chemoresistance in human hepatocellular carcinoma

Yves-Paul VandewynckelO GovaereAster VandierendonckDebby LaukensLindsey DevisscherAnnelies ParidaensEliene BogaertsSarah RaevensXavier VerhelstChristophe Van Steenkiste et al.